A new approach to enhance bioavailability of biologically active peptides: conjugation of a δ opioid agonist to β-cyclodextrin

Maria K. Hristova-Kazmierski, P. Horan, P. Davis, H. I. Yamamura, T. Kramer, R. Horvath, W. M. Kazmierski, F. Porreca, Victor J. Hruby

Research output: Contribution to journalArticle

28 Scopus citations

Abstract

The cyclic δ opioid against [p-I-Phe4]DPDPE, 1, was conjugated to mono-6-amino-permethyl-β-cyclodextrin at the C-terminus to improve the bioavailability of 1. In the rat brain building assay, the conjugate 8 showed an IC50 = 134 nM vs. a δ ligand and IC50 > 10 μM at the μ receptor, making it less potent and selective than 1. However, 8 shows antinociceptive properties (i.v.) in the mouse tail flick test and prolonged activity.

Original languageEnglish (US)
Pages (from-to)831-834
Number of pages4
JournalBioorganic and Medicinal Chemistry Letters
Volume3
Issue number5
DOIs
StatePublished - May 1993

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Medicine
  • Molecular Biology
  • Pharmaceutical Science
  • Drug Discovery
  • Clinical Biochemistry
  • Organic Chemistry

Fingerprint Dive into the research topics of 'A new approach to enhance bioavailability of biologically active peptides: conjugation of a δ opioid agonist to β-cyclodextrin'. Together they form a unique fingerprint.

Cite this